ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

Basic Research Group Seeks $7.9 Billion For NIH, $1.7 For NCI

July 24, 1987

House Committee Begins Investigation Of NCI’s National Lung Screening Trial.

October 26, 2007

Sentinel Lymph Node Excision Has No Impact on Survival

August 26, 2011

In Brief: Newell Denies He’s Leaving For Job On West Coast, Says He Is A “Free Agent”

November 4, 1977

RFA: Long-Term Cancer Survivors

September 12, 1997

In Brief: Rosenberg To Give Karnofsky Lecture at ASCO, Minna To Present Rosenthal Lecture At AACR

April 27, 1984